MYGN Q1 2021 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q1 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$173M+5.5% YoY

Gross Profit

$123M70.9% margin

Operating Income

-$47M-27.0% margin

Net Income

-$40M-22.8% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$72M

Free Cash Flow

$65M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$462M

Stockholders' Equity

$875M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$173M	$164M	+5.5%
Gross Profit	$123M	$114M	+7.8%
Operating Income	-$47M	-$134M	+65.1%
Net Income	-$40M	-$115M	+65.7%

Revenue Segments

Molecular Diagnostic Testing

$160M92%

Molecular Diagnostic Prenatal Testing

$14M8%

Geographic Segments

UNITED STATES

$155M89%

Non-US

$18M11%